FDA approves Akynzeo from Eisai

SILVER SPRING, Md. — The Food and Drug Administration on Friday approved Akynzeo (netupitant and palonosetron) for the treatment of nausea and vomiting in patients who are undergoing cancer chemotherapy. The drug is a fixed-combination capsule of two medications: Oral palonosetron and Netupitant. 

 

“Supportive care products, such as Akynzeo, help ease the nausea and vomiting patients may experience as a side effect of cancer chemotherapy,” said Julie Beitz, M.D., director of the Office of Drug Evaluation III in the FDA’s Center for Drug Evaluation and Research.

 

Akynzeo is distributed and marketed by Eisai.